| Assessment Status | Rapid Review Complete |
| HTA ID | 19049 |
| Drug | Methyl aminolevulinate |
| Brand | Metvix® |
| Indication | For the treatment of: thin or non-hyperkeratotic and non-pigmented actinic keratoses on the face and scalp, when other therapies are considered less appropriate; superficial and/or nodular basal cell carcinoma unsuitable for other available therapies; and squamous cell carcinoma in situ (Bowen´s disease) when surgical excision is considered less appropriate. |
| Assessment Process | |
| Rapid review commissioned | 06/11/2019 |
| Rapid review completed | 18/12/2019 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that methyl aminolevulinate (Metvix®) not be considered for reimbursement at the submitted price*. |
* This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
